Free Trial

Myriad Genetics (MYGN) Competitors

Myriad Genetics logo
$5.62 +0.08 (+1.35%)
As of 01:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MYGN vs. BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, NVAX, GERN, and RGLS

Should you be buying Myriad Genetics stock or one of its competitors? The main competitors of Myriad Genetics include BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.

Myriad Genetics vs. Its Competitors

Myriad Genetics (NASDAQ:MYGN) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Myriad Genetics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

In the previous week, BioCryst Pharmaceuticals had 15 more articles in the media than Myriad Genetics. MarketBeat recorded 16 mentions for BioCryst Pharmaceuticals and 1 mentions for Myriad Genetics. BioCryst Pharmaceuticals' average media sentiment score of 0.53 beat Myriad Genetics' score of 0.00 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Myriad Genetics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioCryst Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BioCryst Pharmaceuticals has a net margin of -10.62% compared to Myriad Genetics' net margin of -12.20%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Myriad Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Myriad Genetics-12.20% -4.95% -3.39%
BioCryst Pharmaceuticals -10.62%N/A -11.06%

99.0% of Myriad Genetics shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 2.1% of Myriad Genetics shares are owned by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has lower revenue, but higher earnings than Myriad Genetics. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Myriad Genetics$837.60M0.62-$127.30M-$1.12-5.02
BioCryst Pharmaceuticals$503.49M3.82-$88.88M-$0.26-35.37

Myriad Genetics presently has a consensus price target of $14.38, suggesting a potential upside of 155.73%. BioCryst Pharmaceuticals has a consensus price target of $16.70, suggesting a potential upside of 81.62%. Given Myriad Genetics' higher probable upside, equities analysts clearly believe Myriad Genetics is more favorable than BioCryst Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics
2 Sell rating(s)
10 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.13
BioCryst Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90

Summary

BioCryst Pharmaceuticals beats Myriad Genetics on 10 of the 16 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYGN vs. The Competition

MetricMyriad GeneticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$520.36M$2.92B$5.54B$9.00B
Dividend YieldN/A2.45%5.25%4.04%
P/E Ratio-5.0421.0327.1820.18
Price / Sales0.62293.12431.49125.05
Price / Cash5.2941.1936.8257.86
Price / Book0.737.758.085.59
Net Income-$127.30M-$54.95M$3.17B$248.60M
7 Day Performance-0.09%5.68%4.13%5.18%
1 Month Performance8.38%5.09%3.80%7.11%
1 Year Performance-77.71%7.54%34.35%21.73%

Myriad Genetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MYGN
Myriad Genetics
4.139 of 5 stars
$5.63
+1.4%
$14.38
+155.7%
-78.0%$520.36M$837.60M-5.042,700
BCRX
BioCryst Pharmaceuticals
4.4635 of 5 stars
$8.96
-4.3%
$16.89
+88.5%
+36.9%$1.87B$450.71M-34.46530
FOLD
Amicus Therapeutics
3.6809 of 5 stars
$5.73
-3.4%
$16.22
+183.1%
-38.8%$1.76B$528.29M-63.66480
CLDX
Celldex Therapeutics
3.0793 of 5 stars
$20.35
+0.3%
$50.11
+146.2%
-41.3%$1.35B$7.02M-7.54150Positive News
INVA
Innoviva
3.8693 of 5 stars
$20.09
+0.7%
$55.00
+173.8%
+16.0%$1.26B$358.71M-19.89100
DVAX
Dynavax Technologies
4.3533 of 5 stars
$9.92
+0.1%
$24.00
+141.9%
-5.3%$1.19B$277.25M-19.08350
MNKD
MannKind
2.5253 of 5 stars
$3.74
-0.5%
$10.33
+176.3%
-32.8%$1.14B$297.60M37.40400Negative News
OPK
OPKO Health
4.537 of 5 stars
$1.32
flat
$2.75
+108.3%
+5.4%$1.05B$713.10M-18.852,997
NVAX
Novavax
4.4907 of 5 stars
$6.30
-1.1%
$17.00
+169.8%
-41.6%$1.02B$682.16M2.381,990
GERN
Geron
2.8466 of 5 stars
$1.41
-5.4%
$5.06
+259.0%
-69.3%$898.06M$76.99M-6.7170Gap Down
RGLS
Regulus Therapeutics
1.5811 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830

Related Companies and Tools


This page (NASDAQ:MYGN) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners